Cassava Sciences Stock News

Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.

Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.

New York, New York--(Newsfile Corp. - August 9, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such inves

The stock lost $75 a share in two days at the end of the month.

Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. The post What to Do After Cassava Sciences Dropped Off a Cliff app

SAVA stock is truly worth paying attention to from here forward as data suggests Cassava Sciences may have solved a big mystery. The post Cassava Sciences May Be Revolutionary in the Alzheimer's Fight

Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advis

Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened.

Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Si

Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the long-time trader made some moves.  Green pointed out the strength of NVIDIA Corporation (NASDAQ:NVDA) Tuesday mor

- Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -

These stocks look to be more trouble than they're worth.

- Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -